Breakthroughs in Immune System Engineering: Oxford’s New Anti-Viral Research Projects
Three research projects focusing on protection against respiratory viruses, led by the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA). These initiatives focus on creating sustained innate immunoprophylactics (SIIPs), a new class of medicines designed to provide durable, broad-spectrum protection against respiratory viruses by engineering the immune system. The funding is part of ARIA’s £57 million Sustained Viral Resilience programme.
The iGATE Project: Smart DNA Medicines for Viral Detection
The iGATE project seeks to develop a new class of smart DNA medicines based on programmable synthetic biosensors. These biosensors are designed to remain inactive in healthy tissue but switch on when responding to viral infection. By combining synthetic biology with artificial intelligence (AI), the team aims to engineer compact gene “circuits” that can detect molecular signs of infection and activate targeted antiviral defences. This approach aims to ultimately reduce the risk of severe disease and hospitalisation.
MDA5-Based Prophylactics: A Broad-Spectrum Defense
A second project focuses on harnessing MDA5, a key sensor in the innate immune system, to develop new prophylactic treatments that could protect against many respiratory viruses, including flu, SARS-CoV-2 responsible for Covid-19 and respiratory syncytial virus. The approach involves coupling this innate signalling pathway with synthetic biology and delivery engineering to create a treatment that, after just one administration, could provide sustained protection against multiple respiratory viruses. Jan Rehwinkel, study lead and professor of innate immunology at Oxford’s MRC Weatherall Institute of Molecular Medicine, emphasized the potential for this method to be effective not just against known viruses, but also against those yet to emerge.
“By coupling this innate signalling pathway with cutting-edge synthetic biology and delivery engineering, we aim to build a prophylactic that we hope to be effective not just against known viruses, but also against those yet to emerge,” Rehwinkel stated. The project will be tested across cell models, human airway organoids and animal systems.
MAGIC Consortium: Boosting Immune Cells for Long-Term Protection
The MAGIC consortium (MAIT activation to Generate Immune Control) targets immune cells called Mucosal-associated invariant T (MAIT) cells. By using synthetic molecules to boost MAIT cells in humans, the team aims to provide longer-lasting protection against various serious infections. The project will bring together collaboration from across the University of Oxford, touching on specialities including physiology, anatomy and genetics.
Why This Matters: Viral Threats and the Race for Solutions
Viruses are diverse in nature, ranging from mild to as devastating as the COVID-19 pandemic. They can devastate both individual health and global economies.
Collaborative Innovation Across Disciplines
All three projects will bring together collaboration from across the University of Oxford, touching on specialities including physiology, anatomy and genetics.
FAQ: Answers to Common Questions
What are SIIPs, and how do they differ from traditional vaccines?
SIIPs (Sustained Innate Immunoprophylactics) are a new class of medicines that provide durable, broad-spectrum protection against respiratory viruses by engineering the immune system.
Explore Oxford’s research initiatives or visit ARIA’s website for detailed project outlines.
What do you think about the future of anti-viral therapies? Share your questions or insights in the comments below. Stay tuned for more updates on groundbreaking medical research.
Related reading